Sugi Predict

Sugi Predict / Compounds / SCHEMBL1119166

SCHEMBL1119166

SCHEMBL1119166

CCCCC=C(CCCCCCCC(=O)O)C(C)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F7 P08709 2/20 0.59
▸ F3 P13726 2/20 0.59
▸ PPARG P37231 8/20 0.55
▸ PPARD Q03181 8/20 0.55
▸ PPARA Q07869 8/20 0.55
▸ GPR84 Q9NQS5 7/20 0.55
▸ HDAC11 Q96DB2 5/20 0.55
▸ TSHR P16473 4/20 0.55
▸ PTPN1 P18031 4/20 0.55
▸ FABP4 P15090 4/20 0.55
▸ HSD17B10 Q99714 3/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ TLR2 O60603 2/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ ALOX15 P16050 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ FABP5 Q01469 2/20 0.55
▸ SLC22A6 Q4U2R8 1/20 0.55
▸ SLC22A8 Q8TCC7 1/20 0.55
▸ MEN1 O00255 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1119162 1.00 F7 (0.59) F7F3PPARGPPARDPPARA
SCHEMBL1119164 1.00 F7 (0.59) F7F3PPARGPPARDPPARA
SCHEMBL1603606 0.95 PPARG (0.62) F7F3PPARGPPARDPPARA
SCHEMBL3887981 0.95 PPARG (0.58) F7F3PPARGPPARDPPARA
SCHEMBL1119181 0.95 PPARG (0.62) F7F3PPARGPPARDPPARA
SCHEMBL1604031 0.95 PPARG (0.62) F7F3PPARGPPARDPPARA
SCHEMBL1119177 0.95 PPARG (0.62) F7F3PPARGPPARDPPARA
SCHEMBL1603608 0.95 PPARG (0.62) F7F3PPARGPPARDPPARA
SCHEMBL1119014 0.95 PPARG (0.62) F7F3PPARGPPARDPPARA
SCHEMBL1119019 0.95 PPARG (0.62) F7F3PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023014748-A1 NITRATED FATTY ACIDS FOR THE TREATMENT OF SICKLE CELL DISORDERS Imara Inc. (US) 2023-02-09 — — WO disclosed
US-20220000824-A1 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION USING THERAPEUTICALLY EFFECTIVE ORAL DOSES OF 10-NITRO-9(E)-OCTADEC-9-ENOIC ACID Imara Inc. 2022-01-06 — — US disclosed
US-20210395184-A1 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA, INC. (US) 2021-12-23 — — US disclosed
CN-113440506-A Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids 康普莱克夏公司 2021-09-28 — — CN disclosed
US-20200308096-A1 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA, INC. (US) 2020-10-01 — — US disclosed
US-20200046669-A1 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION USING THERAPEUTICALLY EFFECTIVE ORAL DOSES OF 10-NITRO-9(E)-OCTADEC-9-ENOIC ACID COMPLEXA, INC. 2020-02-13 — — US disclosed
EP-3355879-A1 PREVENTION, TREATMENT AND REVERSAL OF DISEASE USING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACTIVATED FATTY ACIDS Complexa, Inc. (US) 2018-08-08 — — EP disclosed
US-20170369419-A1 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA, INC. (US) 2017-12-28 — — US disclosed
US-9790167-B2 Vinyl substituted fatty acids COMPLEXA, INC. (US) 2017-10-17 — — US disclosed
US-20170095437-A1 PREVENTION, TREATMENT AND REVERSAL OF DISEASE USING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACTIVATED FATTY ACIDS Imara Inc. 2017-04-06 — — US disclosed
US-20130012583-A1 VINYL SUBSTITUTED FATTY ACIDS UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2013-01-10 — — US disclosed
EP-2280928-A2 VINYL SUBSTITUTED FATTY ACIDS Complexa Inc. (US) 2011-02-09 — — EP disclosed
US-20090326070-A1 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA INC. (US) 2009-12-31 — — US disclosed
WO-2009134383-A2 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA INC. (US) 2009-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200046669-A1 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION USING THERAPEUTICALLY EFFECTIVE ORAL DOSES OF 10-NITRO-9(E)-OCTADEC-9-ENOIC ACID REN, ALOX5, ELOVL5 F7 2720/4885F3 4218/4885PPARG 34/4885
US-20170095437-A1 PREVENTION, TREATMENT AND REVERSAL OF DISEASE USING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACTIVATED FATTY ACIDS REN, ALOX5, ELOVL1 F7 2609/4885F3 4226/4885PPARG 17/4885
US-20200308096-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 F7 326/4885F3 592/4885PPARG 15/4885
US-20170369419-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 F7 326/4885F3 592/4885PPARG 15/4885
US-20130012583-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 F7 326/4885F3 592/4885PPARG 15/4885
US-20220000824-A1 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION USING THERAPEUTICALLY EFFECTIVE ORAL DOSES OF 10-NITRO-9(E)-OCTADEC-9-ENOIC ACID REN, ALOX5, ELOVL5 F7 2720/4885F3 4218/4885PPARG 34/4885
US-20210395184-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 F7 326/4885F3 592/4885PPARG 15/4885
US-20090326070-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 F7 326/4885F3 592/4885PPARG 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.